No Data
Ningbo Menovo Pharmaceutical (603538.SH): Received the Chairman's proposal for the annual dividend for 2024.
On January 23, Gelonghui reported that Ningbo Menovo Pharmaceutical (603538.SH) announced it had received a proposal regarding the 2024 annual dividend from the company's actual controller and Chairman, Mr. Yao Chengzhi. The main content is as follows: "In view of the stable and positive development of the company's production and operation fundamentals in 2024, to actively respond to the 'State Council's Opinions on Strengthening Regulation, Preventing Risks, and Promoting the High-Quality Development of Capital Markets', and to deeply implement regulatory guidelines for listed companies, such as 'Guideline No. 3 for the Regulation of Listed Companies - Cash Dividends for Listed Companies' and the 'Stock Listing Rules of the Shanghai Stock Exchange', to enhance the investment value of listed companies and increase the returns for a broad range of investors."
Ningbo Menovo Pharmaceutical Gets China Approval for Type 2 Diabetes Drug
Ningbo Menovo Pharmaceutical (603538.SH) subsidiary obtained the pharmaceutical registration certificate for Metformin and Vildagliptin Tablets (II).
Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary Ningbo Menovo TianKang Pharmaceutical Co., Ltd. (abbreviation...
Ningbo Menovo Pharmaceutical (603538.SH) and related personnel received a warning letter from the Ningbo Securities Regulatory Bureau.
Ningbo Menovo Pharmaceutical (603538.SH) announced that the company received a notice from the China Securities Regulatory Commission on December 3, 2024...
Ningbo Menovo Pharmaceutical (603538.SH) participated in the selection of Jiangsu Alliance for the fourth and fifth batches of national organized pharmaceutical centralized procurement.
ningbo menovo pharmaceutical (603538.SH) announced that recently, the official website of Jiangsu Provincial Medical Security Bureau released "The 4th-5th batch of national...
Earnings Troubles May Signal Larger Issues for Ningbo Menovo Pharmaceutical (SHSE:603538) Shareholders
Ningbo Menovo Pharmaceutical Co., Ltd.'s (SHSE:603538) Price Is Right But Growth Is Lacking